in vivo animal model studies in biological science
DESCRIPTION
in vivo animal model studies in biological science. Cancer 2. Neuroscience. Cancer research. 2. Neuroscience. Lung Cancer. Cure rate for all patients: 15%. Male. Female. EGFR Expression in NSCLC. Tumours showing high EGFR expression. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/1.jpg)
in vivo animal model studies in biological science
1. Cancer
2. Neuroscience
1. Cancer research
2. Neuroscience
![Page 2: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/2.jpg)
Lung Cancer
• Cure rate for all patients: 15%
Male Female
![Page 3: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/3.jpg)
EGFR Expression in NSCLC
NSCLC 60-80%
Tumours showinghigh EGFR expression
Poor outcome
High expression associated with
![Page 4: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/4.jpg)
EGFR signaling pathways
HER HER
PLC g PI3K
Shc
SosRas
Raf
Mek
PKC
AKT
CyclinD1Elk1
MycSp1
PDK-1
p70S6K
PTEN
FKHR-L1
JAK
STAT
Grb2
p27KIP1Jun/Fos E2F
PEA3
Bad/Bcl2
GSK3
Erk
Citri A, et al. Exp Cell Res 2003
![Page 5: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/5.jpg)
Molecular Targeting of EGF Receptor
Gefitinib (IRESSA) Erlotinib (Tarceva)
Cetuximab
![Page 6: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/6.jpg)
Response to EGFR-TKI in NSCLC patients
Yu CJ. (2005) PloS Med
Initial diagnosis 2 months after gefitinib 9 months later
![Page 7: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/7.jpg)
GxGxxG K
E746-A750
R
768
L R
858
719
G719A/C (5%)
861
L858R (~40%) L861Q (4%)
18 19 20 21 22 23 24
Deletions (~45%)
766-768
Insertions (3%)
776
S768I (2%) R776C (2%)
EGF Ligand Binding
Tyrosine Kinase
TM
Primary activating mutations are mainly found in EGFR tyrosine kinase domain exons 18-21
![Page 8: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/8.jpg)
NSCLCNSCLC
EGFR Mutation(+)
EGFR Mutation(-)
TKIResponse(+)
TKI Response(-)
TKI Response(+)
TKI Response(-)
Response(-)
Primary mutation(s)
( Acquired resistance )
Modeling EGFR-TKI responses in pre-clinical model system
PC9, HCC827
![Page 9: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/9.jpg)
Clinical response to EGFR-TKI in NSCLC patients
Yu CJ. (2005) PloS Med
Initial diagnosis 2 months after gefitinib 9 months later
![Page 10: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/10.jpg)
MET amplification
T790M secondary mutationUnknown Mechanisms
Mechanisms of the Acquired Resistance
to EGFR tyrosine kinase inhibitors in NSCLC (2008)
![Page 11: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/11.jpg)
NSCLCNSCLC
EGFR Mutation(+)
EGFR Mutation(-)
TKIResponse(+)
TKI Response(-)
TKI Response(+)
TKI Response(-)
Response(-)
Primary mutation(s)
( Acquired resistance )
Modeling EGFR-TKI responses in pre-clinical model system
PC9, HCC827
![Page 12: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/12.jpg)
Human cancer cell immunocompromised mouse xenograft model
![Page 13: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/13.jpg)
Erlotinib treatment in PC9 orthotopic lung cancer model
Before administration 1 week
2 weeks 3 weeks
vehicle
erlotinib (50mg/kg/day)
treated
treated
![Page 14: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/14.jpg)
Tumorigenic animals
Treatment duration
Culture succeeded
Tumor regression
Culture failed
Continue treatment
PC9 lung 8 6 months 3 1 4 0
PC9 S. C. 13 5 months 1 0 3 9
HCC827 lung 4 3 months 0 4 0 0
HCC827 S. C. 1 3 months 0 0 0 1
Data summary of erlotinib treatment in pre-clinical animal tumor xenograft model system
![Page 15: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/15.jpg)
PC9TRPC9
Multi-cycle resistance test
Inoculate previously obtained in vivo drug resistant cells tosecond animals and subject the animals to repeated drug cycle
![Page 16: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/16.jpg)
1st generation EGFR-TKI
gefitinib, erlotinb : reversible EGFR blocker
2nd generation EGFR-TKI
e.g. pan-erbB blocker, multi-target EGFR blocker, irreversible EGFR blocker
(BIBW2992)
![Page 17: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/17.jpg)
![Page 18: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/18.jpg)
The Effect on Cell Viability of si-EGFR in PC-BR clones
EGFR
Actinin
scra
msc
ram
scra
msc
ram
si-EGFR
si-EGFR
si-EGFR
si-EGFR
PC9 #10#6#1
EGFR dependentEGFR independent
![Page 19: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/19.jpg)
Q L I T(790)
PC9
Sequencing in PC9 & BR1,6,10
Q L I T(790)
BR#1
Q L I T(790)
BR#6Q L I T(790)
BR#10
![Page 20: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/20.jpg)
Protein expression and phosphorylation profile
in PC9-BR clones
EGFR
Actinin
AKT
ERK
p-EGFR
p-AKT
p-Her3
p-ERK
STAT3
METp-MET
p-STAT3
p70 S6K
BIM
0 0.2 2 20 200
0 0.2 2 20 200 BIBW2992 for24H
0 0.2 2 20 200
PC9 #10#6 0 0.2 2 20 200
#1
20
![Page 21: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/21.jpg)
BIBW2992 treatment in inoculated mouse in vivo
#1 #6
PC #10
![Page 22: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/22.jpg)
in vivo response to BIBW2992
(25mg/kg)
![Page 23: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/23.jpg)
GxGxxG K
E746-A750
R
768
L R
858
719
G719A/C (5%)
861
L858R (~40%) L861Q (4%)
18 19 20 21 22 23 24
Deletions (~45%)
766-768
Insertions (3%)
776
S768I (2%) R776C (2%)
EGF Ligand Binding
Tyrosine Kinase
TM
Primary activating mutations are mainly found in EGFR tyrosine kinase domain exons 18-21
![Page 24: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/24.jpg)
EGFR Mutations
Gefitinib Responders 8/9
Non-responders 0/7 p= 0.00075
Lynch et al, NEJM 2004
![Page 25: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/25.jpg)
Construction of transgenic mouse model
![Page 26: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/26.jpg)
CCSP rtTA
Wong et al. (2006) Cancer Cell
Mouse EGFR non-small cell lung cancer transgenic mouse model
![Page 27: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/27.jpg)
Wong et al. (2006) Cancer Cell
Tet-inducible mutant EGFR expression in mouse lung
![Page 28: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/28.jpg)
Wong et al. (2006) Cancer Cell
EGFR mutation is oncogenic
![Page 29: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/29.jpg)
Wong et al. (2006) Cancer Cell
EGFR expression is required for the maintenance of tumor
![Page 30: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/30.jpg)
Wong et al. (2006) Cancer Cell
![Page 31: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/31.jpg)
Wong et al. (2006) Cancer Cell
Lung cancer originated from mutant EGFR respond to various EGFR inhibitors
![Page 32: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/32.jpg)
Transgenic mutant EGFR animal model study
1. mutant EGFR is oncogenic
2. continued expression of EGFR is required for the maintenance of tumor
3. mutant EGFR is a therapeutic target
![Page 33: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/33.jpg)
Factors controlling tumorigenesis
Immune
Oncogenes Tumor suppressor genes
Stroma Angiogenesis
WT cells
metastasis
![Page 34: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/34.jpg)
![Page 35: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/35.jpg)
Utility of genetically-engineered mouse models of cancer
Geneticallyengineeredmouse
Tumor development
Progression analysis
early detection
prevention
chemotherapy
![Page 36: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/36.jpg)
Genetic engineering of mouse genome : knock-out and knock-in via homologous recombination
![Page 37: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/37.jpg)
![Page 38: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/38.jpg)
Embryonic stem cell culture
![Page 39: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/39.jpg)
Homologous recombinant ES cell selection and blastocyst injection
![Page 40: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/40.jpg)
Generation of chimera mouse
![Page 41: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/41.jpg)
Confirmation of germ line transmission and generation of knock-out(in) mouse
![Page 42: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/42.jpg)
Conditional activation of p53
Advantages:
p53Native promoters Temporal, spatialRegulation of gene expressionunbiased
![Page 43: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/43.jpg)
Conditional knock-out system
![Page 44: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/44.jpg)
P53 LSL/LSL is a phenocopy of p53-/-
Cre-recombinase-Oestrogen-Receptor-T2
![Page 45: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/45.jpg)
![Page 46: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/46.jpg)
![Page 47: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/47.jpg)
![Page 48: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/48.jpg)
![Page 49: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/49.jpg)
![Page 50: in vivo animal model studies in biological science](https://reader035.vdocuments.us/reader035/viewer/2022062410/5681593b550346895dc676f7/html5/thumbnails/50.jpg)
p53 reactivation mouse model study with conditional gene expression mouse
1. p53 inactivation is required for the maintenance of p53 mutant tumors
2. p53 gene delivery or other ways to reactivate p53 in p53 mutant tumor could be a therapeutic option